Efficacy and safety trial of AJG533 in patients with chronic constipation (Phase 3 study)
Phase of Trial: Phase III
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Elobixibat (Primary)
- Indications Constipation
- Focus Registrational; Therapeutic Use
- Sponsors Albireo AB; EA Pharma
- 01 Feb 2017 According to Albireo Pharma media release, based on data from this trial EA Pharma Co. Ltd has submitted a New Drug Application (NDA) to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for elobixibat for the treatment of chronic constipation in Japan.
- 03 Oct 2016 Results published in an Albireo media release.
- 30 Sep 2016 Status changed from recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History